V4cure

Description

V4Cure specializes in the discovery and therapeutic development of innovative peptides derived from animal venoms in the cardio-renal field. V4Cure has a pipeline of innovative drug candidates for diseases of the cardio-renal axis, leveraging the Drug Discovery platform and animal toxins bank of CEA. The first asset of V4Cure is the molecule V4C-232 ,a derivative of a peptide found in venom of the green mamba. It is a new class of V2R antagonists, called aquaretics, acting at the kidney level, to treat disorders related to fluid imbalances. POC studies demonstrate that V4C-232 is the most effective and safe aquaretic solution to treat hyponatremia and progressive polycystic kidney rare diseases.

Company members

Sonia Escaich, Thierry Verrechia, Nicolas Gilles

HealthTech Innovation Days - 6th edition is an event organized by HealthTech For Care.

HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus on advanced medical technologies and innovative drugs. The fund's initiatives and events with a European dimension gather all stakeholders involved in the health innovation value chain, fostering better coordination within the European health ecosystem. HealthTech For Care is administered by a board of European experts.

For any request: contact@htfc-eu.com
Where to find us? Healthtech For Care, 10 Place de Catalogne, 75014 Paris

V4cure

Description

Company members

© HealthTech For Care 2022-2024 - All rights reserved

Cookies Policy

Legal notice

Privacy Policy